Category Archives: DAZZEON Biotech

The ICPG took place in Prague, the Czech Republic from November 8-10, 2023.

The 19th Conference was held in 2023. It continued the ICPG’s long-standing focus on polysaccharides and glycoscience, to which new relevant studies are added. These studies include the structural characteristics and bioactivity of polysaccharides, their technological production, and their application as ingredients in nanoparticles and 3D printing, as well as the chemistry of carbohydrates and polysaccharides, attracting many academics and vendors in the field.

Dazzeon Biotech was invited to present its research results at the ICPG.

BioJapan 2023, the largest biopharmaceutical and healthcare exhibition in Japan and Asia, was grandly held at Pacifico Yokohama from October 11-13, 2023. Among the participating Taiwanese companies, the most discussed was Dazzeon Biotech, a company specializing in plant polymer structures as well as material science and enhancing the activity of plant polysaccharides. Over 51 vendors and government organizations approached the company during the three-day exhibition. The focus was on the global markets for plant-based healthcare and sleep-aiding products, with business opportunities of up to tens of billions of NT dollars.

According to Dazzeon Biotech CEO Dr. Richard Kao, the company achieved fruitful results at the exhibition in Japan, but it also attaches great importance to the domestic market, with a core-technology release forecast for Q4. AlphaSleep’s αSleep Blankets and MannanPRO’s application of plant polysaccharides are two main product lines for the domestic market. Dazzeon Biotech holds a very liberal attitude toward both B2B product co-development and B2C market channel expansion.

What made the exhibition memorable was a visit to Dazzeon Biotech’s booth by Funayama Co., LTD., Japan’s industry leader in firefighting equipment. The company specializes in rescue and disaster prevention and provides professional disaster prevention training at home and abroad, having assisted Taiwan’s Ministry of the Interior and Fire Department in their disaster rescue drills. Funayama President Masanobu Akiyama, after trying the AlphaSleep product series, said they gave the kind of comfort and warming effect he’d never experienced. Therefore, he invited the Dazzeon Biotech team to have a business meeting at Funayama’s headquarters.

During the meeting, the President said that Rescue DAYS JP. would be held next month and that they would use functional blankets made with Dazzeon Biotech’s patented DAZZTEXTM technology in their firefighting training. That way, rescue teams from all over the world would be able to experience the product. This is the beginning of Funayama’s collaboration with Dazzeon Biotech. In the future, the two companies will work together to expand the markets for digestive tract function and sleep products in Taiwan, among other things.

In addition, many international organizations expressed intense interest in Dazzeon Biotech’s products, including the Innovation Agency of Lithuania, the pharmaceutical company affiliated with Itochu Corporation, and Plug and Play, a well-known venture capitalist in Silicon Valley. They considered Dazzeon Biotech a prospective partner in plant polysaccharides. James Tu, Chairman of the Development Center for Biotechnology (DCB), an important R&D legal entity in Taiwan, also visited Dazzeon Biotech’s booth.

Source：The Central News Agency

BioJapan 2023, the largest biopharmaceutical and healthcare exhibition in Japan and Asia, was grandly held at Pacifico Yokohama from October 11-13, 2023. Among the participating Taiwanese companies, the most discussed was Dazzeon Biotech, a company specializing in plant polymer structures as well as material science and enhancing the activity of plant polysaccharides. Over 51 vendors and government organizations approached the company during the three-day exhibition. The focus was on the global markets for plant-based healthcare and sleep-aiding products, with business opportunities of up to tens of billions of NT dollars.

What made the exhibition memorable was a visit to Dazzeon Biotech’s booth by Funayama Co., LTD., Japan’s industry leader in firefighting equipment. The company specializes in rescue and disaster prevention and provides professional disaster prevention training at home and abroad, having assisted Taiwan’s Ministry of the Interior and Fire Department in their disaster rescue drills. Funayama President Masanobu Akiyama, after trying the AlphaSleep product series, said they gave the kind of comfort and warming effect he’d never experienced. Therefore, he invited the Dazzeon Biotech team to have a business meeting at Funayama’s headquarters.

What made the exhibition memorable was a visit to Dazzeon Biotech’s booth by Funayama Co., LTD., Japan’s industry leader in firefighting equipment. The company specializes in rescue and disaster prevention and provides professional disaster prevention training at home and abroad, having assisted Taiwan’s Ministry of the Interior and Fire Department in their disaster rescue drills. Funayama President Masanobu Akiyama, after trying the AlphaSleep product series, said they gave the kind of comfort and warming effect he’d never experienced. Therefore, he invited the Dazzeon Biotech team to have a business meeting at Funayama’s headquarters.

At the exhibition, Dazzeon Biotech also reached cooperation agreement with Japanese institutes such as Hoshi University, the University of Tsukuba, and Tottori University to conduct experiments on the digestive tract and sleep. The institutes also agreed to set up an international R&D center with Dazzeon Biotech in New Taipei City and form an international biotechnology team to conduct in-depth research into digestive tract functions and sleep. Meanwhile, a production center will be established in Japan to facilitate the export of products to Asia and the West.

According to Dazzeon Biotech CEO Dr. Richard Kao, the company achieved fruitful results at the exhibition, but it also attaches great importance to the domestic market, with a core-technology release forecast for Q4. AlphaSleep’s αSleep Blankets with nanonization technology and MannanPRO’s application of plant polysaccharides are two main product lines for the domestic market. Dazzeon Biotech holds an open attitude toward both B2B product co-development and B2C market channel expansion. As long as companies value data verification and aim to bring consumers high-standard, high-quality products and services, they are welcome to approach Dazzeon Biotech for collaboration.

Source：Economic Daily News

Dazzeon Biotech, which started off by researching plant polymer structures and material science as well as increasing the activity of plant polysaccharides, is one of the very few biotech companies in Taiwan that can merge plant polysaccharides and material science. It also puts a premium on clinical data. The company is set to demonstrate the result of commercializing its two core technologies, MannanPRO and AlphaSleep. By integrating plant polysaccharides with material science, the company has launched more natural and simpler solutions to digestive tract function and sleep problems compared with existing solutions. Moreover, the company was invited to BioJapan 2023, the largest biopharmaceutical and healthcare exhibition in Japan and Asia, making it a high-profile company in Taiwan, Japan, and the Asia-Pacific region.

Dazzeon Biotech’s AlphaSleep has a product line of αSleep Blankets, a key result of the commercialization of the company’s nano size reduction technology. The product applies AlphaSleep Power, an energy wavelength that can increase whole-body circulation. Another product line, MannanPRO, applies plant polysaccharides and has been patented in the U.S., Taiwan, and China, better utilizing the natural power of aloes.

Dr. Richard Kao, CEO of Dazzeon Biotech, also said, “According to a CDC report released in April 2021, the number of people worldwide affected by digestive tract problems is about 7 million. The global market size is estimated to be $25 billion. Dazzeon Biotech’s goal is to provide groundbreaking solutions.” Thus, the company has set up an international R&D center in the New Taipei Industrial Park. Its research partners are located in the Netherlands, Germany, Belgium, and Japan. Among them, GFP, an expert in mushroom polysaccharides from Germany, and S&K, a healthy chocolate brand from the Czech Republic, are some of the multinational companies that have started business collaboration in view of the purity of the products, literature, and the huge number of precise experimental data indicators that Dazzeon Biotech’s R&D team offers.

Dazzeon Biotech is going to Japan to participate in Asia’s largest biotechnology and pharmaceutical exhibition, which will be held at Pacifico Yokohama, Japan, from October 11-13, 2023. Three thematic exhibitions are held together, and this year marks the 25th anniversary of the event. With international exchanges such as exhibitions, seminars, and business matchmaking, the company believes that it can demonstrate Taiwan’s strong biotechnology R&D capabilities in the global biotechnology market through the commercialization of its two core technologies, MannanPRO and AlphaSleep.

Source：Economic Daily News

A report published by the Taiwan Food and Drug Administration indicates that more than 50% of the people in Taiwan fail to take good care of their dietary habits. They always eat out, taking a toll on their body. Statistics from the World Sleep Society (WSS) and the Taiwan Society of Sleep Medicine (TSSM) also show that the prevalence of insomnia in Taiwan is about 17%. In other words, an estimated 3.91 million people are insomniacs.

Dazzeon Biotech, which started off by researching plant polymer structures and material science as well as increasing the activity of plant polysaccharides, is one of the very few biotech companies in Taiwan that can merge plant polysaccharides and material science. It also puts a premium on clinical data. The company is set to demonstrate the result of commercializing its two core technologies, MannanPRO and AlphaSleep. By integrating plant polysaccharides with material science, the company has launched more natural and simpler solutions to digestive tract function and sleep problems compared with existing solutions. Moreover, the company was invited to BioJapan 2023, the largest biopharmaceutical and healthcare exhibition in Japan and Asia, making it a high-profile company in Taiwan, Japan, and the Asia-Pacific region.

Dazzeon Biotech’s AlphaSleep has a product line of αSleep Blankets, a key result of the commercialization of the company’s nanonization technology. The product applies AlphaSleep Power, an energy wavelength. Another product line, MannanPRO, applies plant polysaccharides, better utilizing the natural power of aloes. It has been patented in the U.S., Taiwan, and China.

“According to a CDC report released in April 2021, the number of people worldwide affected by digestive tract problems is about 7 million. The global market size is estimated to be $25 billion. As a result, Dazzeon Biotech’s goal is to provide groundbreaking solutions,” said Dr. Richard Kao, CEO of Dazzeon Biotech.

Dazzeon Biotech has set up an international R&D center in the New Taipei Industrial Park, and its research partners are located in the Netherlands, Germany, Belgium, and Japan. Among them, GFP, an expert in mushroom polysaccharides from Germany, and S&K, a healthy chocolate brand from the Czech Republic, are some of the multinational companies that have started business collaboration in view of the purity of the products, literature, and the huge number of precise experimental data indicators that Dazzeon Biotech’s R&D team offers.

Dazzeon Biotech is going to Japan to participate in Asia’s largest biotechnology and pharmaceutical exhibition, which will be held at Pacifico Yokohama, Japan, from October 11-13, 2023. Three thematic exhibitions are held together, and this year marks the 25th anniversary of the event. With international exchanges such as exhibitions, seminars, and business matchmaking, the company believes that it can demonstrate Taiwan’s strong biotechnology R&D capabilities in the global biotechnology market through the commercialization of its two core technologies, MannanPRO and AlphaSleep.

Source：The Commercial Times